In the last trading session, 1.89 million shares of the Legend Biotech Corp ADR (NASDAQ:LEGN) were traded, and its beta was 0.26. Most recently the company’s share price was $37.49, and it changed around $1.62 or 4.52% from the last close, which brings the market valuation of the company to $6.90B. LEGN currently trades at a discount to its 52-week high of $60.87, offering almost -62.36% off that amount. The share price’s 52-week low was $27.34, which indicates that the current value has risen by an impressive 27.07% since then. We note from Legend Biotech Corp ADR’s average daily trading volume that its 10-day average is 1.67 million shares, with the 3-month average coming to 1.80 million.
Legend Biotech Corp ADR stock received a consensus recommendation rating of Buy, based on a mean score of 1.20. If we narrow it down even further, the data shows that 0 out of 22 analysts rate the stock as a Sell; another 9 rate it as Overweight. Among the rest, 1 recommended LEGN as a Hold, whereas 12 deemed it a Buy, and 0 rated it as Underweight.
Legend Biotech Corp ADR (NASDAQ:LEGN) trade information
Instantly LEGN has showed a green trend with a performance of 4.52% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 37.81 on recent trading dayincreased the stock’s daily price by 0.85%. The company’s shares are currently down -18.34% year-to-date, but still up 5.64% over the last five days. On the other hand, Legend Biotech Corp ADR (NASDAQ:LEGN) is 19.09% up in the 30-day period. We can see from the shorts that 14.37 million shares have been sold at a short interest cover period of 6.39 day(s).
The consensus price target as assigned by Wall Street analysts is $64.5, which translates to bulls needing to increase their stock price by 41.88% from its current value. Analyst projections state that LEGN is forecast to be at a low of $54 and a high of $75.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 0.79%.
LEGN Dividends
Legend Biotech Corp ADR’s next quarterly earnings report is expected to be released on 2025-May-13.
Legend Biotech Corp ADR (NASDAQ:LEGN)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.33% of Legend Biotech Corp ADR shares, and 47.77% of them are in the hands of institutional investors. The stock currently has a share float of 48.42%. Legend Biotech Corp ADR stock is held by 338.0 institutions, with FMR LLC being the largest institutional investor. By 2024-06-30, it held 9.6503% of the shares, which is about 17.62 million shares worth $780.46 million.
PRICE T ROWE ASSOCIATES INC /MD/, with 6.292% or 11.49 million shares worth $508.86 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
